Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction

Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction

Background: Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. The effect of sodium-glucose cotransporter 2 inhibitors in patients with HF with preserved ejection fraction according to...

Full description

Bibliographic Details
Main Authors: Anker, S.D (Author), Butler, J. (Author), Ferreira, J.P (Author), Filippatos, G. (Author), Januzzi, J.L (Author), Packer, M. (Author), Pocock, S. (Author), Schueler, E. (Author), Steubl, D. (Author), Zannad, F. (Author), Zeller, C. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
aged
agents affecting metabolism
Article
cardiovascular mortality
comparative effectiveness
controlled study
drug efficacy
drug use
empagliflozin
female
heart failure with preserved ejection fraction
heart left ventricle ejection fraction
hospitalization
human
hyperkalemia
major clinical study
male
mineralocorticoid antagonist
mineralocorticoid receptor antagonists
outcome assessment
placebo
potassium binder
recurrent disease
risk reduction
survival rate
treatment effect
unclassified drug
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items